STOCK TITAN

Halozyme CEO Helen Torley sells 60,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Halozyme Therapeutics president and CEO Helen Torley exercised stock options covering 60,000 shares and sold 60,000 common shares across November 12, November 13, and November 16, 2026. The options had exercise prices of $16.65 and $18.41 per share. The exercises and sales were made under a written Rule 10b5-1 trading plan adopted December 3, 2025.

Insider Torley Helen
Role PRESIDENT AND CEO
Sold 60,000 shs ($6.00M)
Approx. gross sale proceeds $6.00M
Approx. exercise cost $1.04M
Approx. pre-tax spread $4.96M
Type Security Shares Price Value
Exercise Option to Purchase Common Stock F1, F12 20,000 $16.65 $333K
Exercise Common Stock F1 20,000 $16.65 $333K
Sale Common Stock F1, F6 7,283 $96.848 $705K
Sale Common Stock F1, F7 4,802 $97.955 $470K
Sale Common Stock F1, F8 1,586 $98.891 $157K
Sale Common Stock F1, F9 4,897 $100.096 $490K
Sale Common Stock F1, F10 1,244 $101.059 $126K
Sale Common Stock F1 188 $101.72 $19K
Exercise Option to Purchase Common Stock F1, F11 1,552 $18.41 $29K
Exercise Option to Purchase Common Stock F1, F12 18,448 $16.65 $307K
Exercise Common Stock F1 1,552 $18.41 $29K
Exercise Common Stock F1 18,448 $16.65 $307K
Sale Common Stock F1, F4 7,992 $100.019 $799K
Sale Common Stock F1, F5 12,008 $100.614 $1.21M
Exercise Option to Purchase Common Stock F1, F11 20,000 $18.41 $368K
Exercise Common Stock F1 20,000 $18.41 $368K
Sale Common Stock F1, F2 10,711 $101.093 $1.08M
Sale Common Stock F1, F3 9,289 $101.494 $943K
Holdings After Transaction: Option to Purchase Common Stock — 211,770 options (Direct); Common Stock — 767,780 shares (Direct)
Footnotes (12)
  1. F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year terms expiring in February 2028 and February 2029.
  2. F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.340 to $101.330. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.340 to $101.940. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. F4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.337 to $100.330. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. F5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.360 to $101.066. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. F6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $96.440 to $97.420. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  7. F7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $97.490 to $98.450. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  8. F8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.520 to $99.380. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  9. F9. Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.703 to $100.650. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  10. F10. Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.710 to $101.643. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  11. F11. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.
  12. F12. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 12, 2019.
Options exercised 60,000 shares Across November 12, November 13, and November 16, 2026
Shares sold 60,000 shares Across November 12, November 13, and November 16, 2026
Option exercise prices $16.65 and $18.41 per share Options exercised in November 2026
Rule 10b5-1 regulatory
"written trading plan adopted December 3, 2025"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted average sales price financial
"Represents a weighted average sales price per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HALO shares did CEO Helen Torley sell?

Helen Torley sold 60,000 shares across November 12, November 13, and November 16, 2026, after exercising options covering the same number of shares. The reported sales were made under a written Rule 10b5-1 trading plan adopted December 3, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Torley Helen

(Last)(First)(Middle)
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
PRESIDENT AND CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/12/2026M(1)20,000A$18.41787,780D
Common Stock11/12/2026S(1)10,711D$101.093(2)777,069D
Common Stock11/12/2026S(1)9,289D$101.494(3)767,780D
Common Stock11/13/2026M(1)1,552A$18.41769,332D
Common Stock11/13/2026M(1)18,448A$16.65787,780D
Common Stock11/13/2026S(1)7,992D$100.019(4)779,788D
Common Stock11/13/2026S(1)12,008D$100.614(5)767,780D
Common Stock11/16/2026M(1)20,000A$16.65787,780D
Common Stock11/16/2026S(1)7,283D$96.848(6)780,497D
Common Stock11/16/2026S(1)4,802D$97.955(7)775,695D
Common Stock11/16/2026S(1)1,586D$98.891(8)774,109D
Common Stock11/16/2026S(1)4,897D$100.096(9)769,212D
Common Stock11/16/2026S(1)1,244D$101.059(10)767,968D
Common Stock11/16/2026S(1)188D$101.72767,780D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase Common Stock$18.4111/12/2026M(1)20,000 (11)02/14/2028Common Stock20,000$18.411,552D
Option to Purchase Common Stock$18.4111/13/2026M(1)1,552 (11)02/14/2028Common Stock1,552$18.410D
Option to Purchase Common Stock$16.6511/13/2026M(1)18,448 (12)02/12/2029Common Stock18,448$16.65231,770D
Option to Purchase Common Stock$16.6511/16/2026M(1)20,000 (12)02/12/2029Common Stock20,000$16.65211,770D
Explanation of Responses:
1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year terms expiring in February 2028 and February 2029.
2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.340 to $101.330. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.340 to $101.940. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.337 to $100.330. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.360 to $101.066. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $96.440 to $97.420. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $97.490 to $98.450. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.520 to $99.380. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
9. Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.703 to $100.650. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
10. Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.710 to $101.643. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
11. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.
12. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 12, 2019.
Remarks:
/s/ James R. Oehler, Attorney-in-Fact11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading